Synthetic data is moving from point solutions to governed pipelines: reviews show fast adoption across healthcare and manufacturing, while policy and ethics groups push for clearer quality, bias, and privacy controls.
A Scoping Review of Synthetic Data Generation by Language Models in Biomedical Research
An arXiv scoping review surveys 59 studies (2020–2025) using large language models to generate synthetic biomedical data, spanning unstructured text, tabular, and multimodal settings. The work frames LLM-based synthesis as a response to data scarcity and privacy constraints common in clinical and research datasets. It also flags recurring gaps around evaluation practices and accessibility, which makes results hard to compare across papers and deployments.
- Data teams should expect scrutiny on evaluation: utility metrics, privacy testing, and documentation need to be standardized to be credible.
- Healthcare buyers will increasingly ask whether synthetic text/tabular data can be audited and reproduced, not just whether it “works.”
- Founders building LLM-based synthesis tools may differentiate on benchmarking harnesses and governance features rather than model novelty.
Synthetic Data: The New Data Frontier
The World Economic Forum’s strategic brief positions synthetic data as a way to reduce barriers from limited access, bias, and privacy restrictions, while emphasizing governance, quality control, and hybrid real-synthetic approaches. The document reads as a playbook for leaders: treat synthetic data as a managed asset with clear ownership, controls, and fit-for-purpose validation. It implicitly raises the bar for “responsible” generation beyond one-off model training boosts.
- Compliance leads can use this framing to formalize policies: when synthetic data is allowed, how it’s validated, and how it’s monitored over time.
- Hybrid strategies (real + synthetic) may become the default procurement requirement in regulated sectors like healthcare and finance.
- Teams should budget for ongoing quality assurance—drift and bias checks don’t disappear just because data is synthetic.
Synthetic data generation in manufacturing: a review of methods, domains, and modalities
A DTU Orbit review analyzes 18 papers (Jan 2024–May 2025) on synthetic data generation in manufacturing, categorizing techniques, applications, and data types. The focus is practical: industrial environments often face sparse labels, proprietary constraints, and heterogeneous sensor/vision data. The review helps map where synthesis is being applied and which modalities are getting attention.
- Industrial ML teams can use the taxonomy to choose methods by modality (e.g., sensor vs. vision) and deployment constraints.
- Privacy and IP concerns in factories mirror healthcare: governance patterns can transfer across sectors.
A Little Human Data Goes A Long Way
An ACL paper reports that mixing small amounts of human data with synthetic data improves performance in fact verification and evidence-based question answering. The takeaway is operational: synthetic data can amplify limited real datasets rather than replace them. That matters for teams trying to reduce exposure to sensitive or costly-to-label data while keeping task performance competitive.
- For privacy programs, “minimal real data + synthetic augmentation” is a concrete design pattern to test.
- For evaluation, it pushes teams to measure marginal gains from small real sets, not only synthetic-only results.
Synthetic data created by generative AI poses ethical challenges
NIEHS highlights ethical challenges in generative-AI-driven synthetic data, noting a long history of synthetic data use while emphasizing newer privacy, bias, and utility risks in health research. The piece underscores that synthetic outputs can still encode sensitive patterns or propagate harmful bias if generation and validation are weak. It reinforces that ethics and governance are now part of the technical acceptance criteria.
- Public health and clinical teams should document intended use, limitations, and bias testing as part of release workflows.
- Regulators and IRBs may increasingly treat synthetic datasets as governed artifacts, not “free-to-share” data.